Targeting Cancer Pathways Series

Cell Signaling Technology is proud to partner with the Koch Institute at MIT to present the Annual Signaling in Cancer Symposium. This meeting brings together cancer research thought leaders from around the world to share current findings and further research community collaboration.

This year the symposium is titled “Targeting Signaling Pathways.” It will include three webinars spaced throughout the year and will culminate with a live event webcast from the Koch Institute at MIT in Cambridge, MA.

Targeting the Tumor Microenvironment

This webinar is the second in a series focusing on the cancer pathways that support tumor development, the emerging research in identifying and targeting these pathways, and innovations in the development of increasingly effective cancer therapy options. Recent advances in our understanding of cancer have revealed that the disease cannot be understood through simple analysis of genetic mutations within cancerous cells. Instead, tumors should be considered complex tissues in which the cancer cells communicate with the surrounding cellular microenvironment and evolve traits that promote their own survival. Here, we will explore how the tumor microenvironment promotes oncogenic progression, while protecting the tumor from therapeutic intervention. By better understanding the tumor microenvironment we can develop strategies and treatment options to neutralize its oncogenic influence and more effectively attack the tumor itself.

Featured speakers

Padmanee Sharma Rakesh Jain

Padmanee Sharma, M.D., Ph.D The University of Texas MD Anderson Cancer Center, Houston, TX.

Rakesh Jain, Ph.D Massachusetts General Hospital, Harvard Medical School, Boston, MA


October 22nd, 2014. Targeting Cancer Pathways: Mechanisms of Tumor Resistance

Previously Recorded: View Online Now!

Here, we will examine how the rewiring of signaling pathways, in response to drug treatment, contributes to tumor resistance and how this knowledge can inform the development of more effective treatment strategies. During this webinar, viewers will:

  • Gain an understanding of the specific molecules and pathways that are the targets for rationally designed therapies
  • Learn about development of the first FDA-approved therapy targeting a hyperactive kinase
  • Review mechanisms by which tumor cells resist inhibitors that target the PI3K cell survival pathway or the EGFR receptor
  • Hear how the rewiring of cell death pathways can sensitize cells to traditional chemotherapy agents
  • Have their questions answered live by the expert panel.

Featured speakers

Yaffe Engelman Deininger
Michael B. Yaffe, M.D., Ph.D. Massachusetts Institute of Technology, Cambridge, MA Jeffrey Engelman, M.D., Ph.D., Harvard Medical School, Boston, MA Michael W. Deininger, M.D., Ph.D., University of Utah, Salt Lake City, UT


June 10th, 2015. Tumor Metabolism and Proliferation

June 10th, 2015. Targeting Cancer Pathways: Tumor Metabolism and Proliferation Speakers: TBA